Study design and patients
obesity, death, HC, stroke, deaths
OBESITY, STROKE, MYOCARDIAL INFARCTION, CREST
Data from the placebo group of the REWIND trial were used for this analysis. Details of the REWIND trial are published elsewhere [Weight measurements were taken at baseline and throughout the trial annually as well as at the final study visit. Height, waist circumference, and hip circumference were measured at baseline and every 24 months throughout the trial as well as at the final study visit. To calculate BMI, body weight and height were measured. Body weight was measured using a calibrated scale (mechanical or digital). BMI was calculated as weight in kilograms divided by the square of height in meters. WC and hip circumference (HC) measurements were obtained with the patient in the standing position. WC was measured immediately above the iliac crest and HC at the maximal circumference of the buttocks, both in centimeters. WHR was calculated by dividing WC by HC.The current analysis examined obesity measures, measured at baseline, as potential risk factors for four outcomes: MACE-3 (non-fatal myocardial infarction, non-fatal stroke, or death from CV causes including unknown causes), CVD-related mortality, all-cause mortality, and HF requiring hospitalization or urgent care. Potential CV outcomes and all deaths were adjudicated by an independent clinical endpoint committee that was masked to treatment assignment. Further adjudication criteria are published elsewhere [